WKWon Ki Kang

Won Ki Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Won Ki Kang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Inkyoung Lee

    Samsung Biomedical Research Institute Sungkyunkwan University School of Medicine Seoul Korea

    4 shared publications
  • Chaehwa Park

    Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    3 shared publications
  • H.Y. Lim

    Division of Hematology/Oncology

    2 shared publications
  • J. Lee

    Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    2 shared publications
  • J.O. Park

    Division of Hematology/Oncology

    2 shared publications
  • Jin Seok Ahn

    Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Seoul, Korea

    2 shared publications

Latest Publications

  • A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.

    by Yoon-Koo Kang, Narikazu Boku, Won Ki Kang, Harry H. Yoon, Stefano Cascinu, Salah-Eddin Al-Batran, Scott Houston, Cheol Hee Park, Arlo N. McGinn, Ian Chau

    TPS4138 Background: Apatinib is an orally administered, highly selective tyrosine kinase inhibitor of VEGFR-2 that has been studied in many clinical trials, primarily in China, treating various solid tumors. Based on the results of the Chinese Phase 3 study, apatinib was approved in China for the treatment of advanced gastric cancer (GC), but apatinib has yet to be evaluated in a randomized placebo-controlled study in the rest of the world. ANGEL is a multinational, placebo controlled, Phase 3 study investigating the efficacy and safety of apatinib in advanced GC patients in North America, Europe, and Asia Pacific. Methods: Main eligibility criteria include patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction for whom at least 2 prior lines of standard chemotherapy had failed, ECOG performance status ≤ 1, and disease progression < 6 months after last chemotherapy treatment. Approximately 459 patients will be randomized in a 2:1 ratio to receive continuous 28-day cycles of apatinib 700 mg or a matched placebo daily with best supportive care until disease progression, intolerable toxicity or withdrawal of consent. Stratification factors include geographic region (Asia vs. North America/Europe), disease measurability, prior ramucirumab treatment, and treatment therapy line (3rd or 4th). Primary endpoint is overall survival (OS) in the intent-to-treat population, and secondary endpoints are progression free survival (PFS), objective response rate (ORR), disease control rate (DCR), quality of life, and safety. The primary analysis of OS will be conducted in intention-to-treat population using a stratified log-rank test at the two-sided alpha = 0.05 level of significance. If the primary analysis of OS is statistically significant, then PFS and ORR will be analyzed. All other secondary efficacy endpoints will be analyzed using two-sided tests at the alpha = 0.05 level of significance. Enrollment opened Feb 2017. Clinical trial information: NCT03042611.


  • Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.

    by Min-Hee Ryu, Eishi Baba, Kyung Hee Lee, Narikazu Boku, Young Iee Park, Ichinosuke Hyodo, Byung-Ho Nam, Taito Esaki, Baek-Yeol Ryoo, Eun-Kee Song, et al.

    LBA4024 Background: 5-weekly S-1 plus cisplatin (SP5: S-1 80-120 mg/body/day on D1-21, cisplatin 60 mg/m2 on D8, every 5 weeks) has become a standard first-line chemotherapy for AGC in Japan based on the SPIRITS trial (Lancet Oncol. 2008;9:215). To strengthen the low-dose intensity of cisplatin in this SP5 for greater efficacy, a 3-weekly S-1 plus cisplatin (SP3: S-1 80 mg/m2/day on D1-14, cisplatin 60 mg/m2on D1, every 3 weeks) has been developed in Korea (Cancer Chemother Pharmacol. 2008;61:837). Methods: This SOS study was a multicenter, randomized, open-label, phase III study to evaluate whether SP3 was non-inferior/superior to SP5 in terms of progression-free survival (PFS) determined by a blinded central radiology review according to RECIST v1.1. Patients (pts) with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma and with no prior chemotherapy were randomized 1:1 to receive either SP3 or SP5 until disease progression or unacceptable toxicities. Results: Between February 2009 and January 2012, a total of 625 pts were randomized from 42 sites in Korea and Japan. Median age was 59.6 years. 99% of pts had ECOG performance status 0-1. 16% of pts had prior gastrectomy. 62% of pts had measurable lesions. With a median follow-up of 34.7 months (range, 14.2-48.8) in surviving pts, SP3 was significantly noninferior and superior to SP5 in PFS (median 5.5 months vs. 4.9 months; HR 0.82, 95% CI 0.68-0.99, p=0.0418). Overall response rate (ORR) was also better with SP3 than with SP5 (60% vs. 50%, p=0.029). However, OS of both groups was equivalent (median 14.1 vs. 13.9 months; HR 0.99, 95% CI 0.81-1.21, p=0.9068). Treatment was well tolerated in both arms, while SP3 was associated with more frequent G3/4 anemia (19% vs. 9%) and neutropenia (39% vs. 9%). Dose intensity was higher in SP3 than in SP5 for both agents (median 331 vs. 317 mg/m2/week for S-1, p2/week for cisplatin, p<0.001). Conclusions: SP3 was noninferior and superior to SP5 in terms of PFS and ORR. However, considering the small benefit in PFS and no difference in OS, both SP3 and SP5 can be recommended for the first-line treatment of AGC. Clinical trial information: NCT00915382.


  • Open Access

    PD2-2-3: Prognostic significance of L1 cell adhesion molecule (CAM) expression in pulmonary neuroendocrine tumors

    by Hyo Song Kim, Keunchil Park, Hyun Jung Jun, Seong Yoon Yi, Joungho Han, Jin Seok Ahn, Myung-Ju Ahn, Won Ki Kang, Jinman Kim, Hyo-Jeong Hong

  • Open Access

    Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

    by J. Lee, T. Lim, J.E. Uhm, K.W. Park, S.H. Park, S.C. Lee, J.O. Park, Y.S. Park, H.Y. Lim, T.S. Sohn, et al.

    Background: This study was to devise a prognostic model for metastatic gastric cancer patients undergoing first-line chemotherapy. Patients and methods: A retrospective analysis was carried out on 1455 gastric cancer patients, who received first-line chemotherapy from September 1994 to February 2005. Results: At multivariate level, poor prognostic factors were no previous gastrectomy [P = 0.003; relative risk (RR), 1.191; 95% confidence interval (CI) 1.061–1.338], albumin P = 85 U/l (P = P = P = 0.001; RR, 1.460; 95% CI 1.616–1.836), and the presence of ascites (P = Conclusions: This model should facilitate the individual patient risk stratification and thus, more appropriate therapies for each metastatic gastric cancer patient.


  • Open Access

    Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma

    by J. Lee, W.K. Kang, J.M. Kwon, S.Y. Oh, H.R. Lee, H.J. Kim, B.B. Park, H.Y. Lim, M.J. Han, J.O. Park, et al.

    Background: This nonrandomized open label phase II study evaluated the efficacy and safety of FOLFOXIRI in metastatic or recurrent gastric cancer patients. Patients and methods: Patients with histologically proven, metastatic gastric adenocarcinoma, aged 18–70 years, performance status zero to two, no prior chemotherapy, and with signed written informed consent were eligible. Treatment consisted of irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, leucovorin 100 mg/m2 day 1, and 5-fluorouracil 2000 mg/m2 as a 48-h continuous infusion starting on day 1, which was repeated every 2 weeks. Results: From August 2004 to August 2005, 48 patients were prospectively enrolled. The median age was 54 years (24–69). In total, 386 cycles were administered with a median of nine cycles per patient (range 1–12 cycles) and 45 of 48 patients were assessable for treatment response. An independent review of tumor responses resulted in overall response rate of 66.7% (95% confidence interval = 53.4% to 80.0%) by intent-to-treat analysis with one complete response and 31 partial responses. The median survival of all patients was 14.8 months and the median time to progression was 9.6 months. Most common grade 3/4 toxic effects were neutropenia (12% of all cycles) and emesis (8% of all cycles). Grade 2 peripheral neuropathy occurred in five patients. One (2%) patient had severe tumor bleeding and five (10%) patients experienced grade 3 diarrhea. Conclusions: The modified FOLFOXIRI combination chemotherapy showed a very promising preliminary antitumor activity and was generally well tolerated as a first-line treatment of patients with metastatic gastric cancer.


  • Open Access

    E2F-1 is a critical modulator of cellular senescence in human cancer

    by Chaehwa Park, Inkyoung Lee, Won Ki Kang

    Senescence limits cellular proliferation, and therefore might be a mechanism which could suppress the progression of cancer. Herein we show that E2F1, a transcription factor essential to a cell cycle progress and a main target of tumor suppressor Rb, is a critical barrier for the induction of senescence. Human cancer cells transfected with siE2F1 were shown to express replicative senescence markers, in addition to yielding positive results upon SA-beta-Gal staining. Consistent with the notion of the critical role in senescence of E2F1, cells which overexpressed E2F1 proved to be immune to the induction of senescence. Importantly, it appears that E2F1 depletion-induced cancer cell senescence is not reliant on the integrity of either Rb or p53. Our results provide a molecular explanation for the selectivity with which senescence induction occurs, and also provides insights into the possibility of using E2F1 as a therapeutic target in the treatment of cancer.


  • Open Access

    Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial

    by Tae Won Kim, Won Ki Kang, Heung Moon Chang, Joon Oh Park, Baek Yeol Ryoo, Jin Seok Ahn, Dae Young Zang, Kyung Hee Lee, Yoon Koo Kang, Sung Rok Kim, et al.

    A phase II study was conducted to assess the efficacy and tolerability of capecitabine in combination with irinotecan (CAPIRI) in advanced colorectal cancer. Forty-seven patients with previously untreated metastatic or unresectable colorectal adenocarcinoma received capecitabine 1000 mg/m2 twice daily on days 2–15 and intravenous irinotecan 100 mg/m2 on days 1 and 8, every 21 days. A total of 268 cycles of chemotherapy (median 6: range 1–11) were administered. According to an intent-to-treat analysis, the overall response rate was 49% (95% CI, 35–63%). Median time to progression and overall survival were 7.5 months (95% CI, 4.8–10.2) and 19.5 months (95% CI, 15.7–23.8), respectively. The most common grade 3/4 adverse events were diarrhea (24%) and neutropenia (11%). There were no treatment-related deaths. These results indicate that CAPIRI has comparable activity and tolerability to FOLFIRI as first-line treatment for advanced colorectal cancer.


    • 1 February 2005
      • Vol. 13  (2) , 299-304

    Differential effects of RhoA signaling on anticancer agent-induced cell death.

    by Won Ki Kang, Inkyoung Lee, Ukyoung Ko, Chaehwa Park

    Substantial evidence exists to support a role for RhoA signaling in adhesion and cytoskeletal reorganization, while relatively less is known about the participation of RhoA on cell survival. We provide evidence that RhoA functions as a differential modulator of apoptosis induced by anticancer agents. Specifically, both RhoA and caRhoA induce statistically significant resistance to statin, etoposide, 5-FU and taxol while increasing sensitivity to vincristine (all p<0.001). The IC50 values for statin, etoposide, 5-fluorouracil (5-FU) and taxol in caRhoA transfectant were 8.70+/-0.74, 4.08+/-0.12, 4.12+/-0.12 microg/ml and 3.84+/-0.16 ng/ml, respectively, whereas the respective IC50 values in the mock-transfected control were 3.40+/-0.21, 1.12+/-0.06, 1.21+/-0.06 microg/ml and 2.84+/-0.15 ng/ml. This represented a 2.6-, 3.5-, 3.2- and 1.4-fold resistance to statin, etoposide, 5-FU and taxol, respectively. In contrast, caRhoA increased sensitivity to vincristine, decreasing IC50 values from 4.61+/-0.46 to 3.73+/-0.44 ng/ml (p<0.001). Western blot analysis demonstrated that RhoA mediates induction of E2F-1, Cdk2 and PCNA, accompanying concurrent reduction in p21 and p27. However, cleavage assays of poly (ADP-ribose) polymerase, BID, caspase-8 and caspase-3 indicate that the cell growth modulation mediated by RhoA in response to these anticancer agents occurs through the inhibition of apoptosis. Taken together, these results indicate that RhoA differentially modulates cancer cell death depending on the anticancer agent.


  • Open Access

    Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

    by S-H Lee, W K Kang, J Park, H Y Kim, J H Kim, S I Lee, J O Park, K Kim, C W Jung, Y S Park, et al.